AstraZeneca (LSE:AZN) has won European Commission approval for Etcamah (camizestrant) in combination with a CDK4/6 inhibitor as a first-line treatment for adults with ER-positive, HER2-negative advanced breast cancer who develop an ESR1 gene mutation while on initial endocrine therapy.
The approval rests on the Phase III SERENA-6 trial, published in the New England Journal of Medicine, which showed the combination cut the risk of disease progression or death by 56% against standard aromatase inhibitor therapy, extending median progression-free survival to 16.0 months from 9.2 months.
Etcamah becomes the only next-generation oral selective estrogen receptor degrader approved for first-line use alongside all three widely prescribed CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib.
"The approval of the Etcamah combination marks an important shift in the 1st-line treatment paradigm for patients with ER-positive, HER2-negative advanced breast cancer in Europe," said Dave Fredrickson, AstraZeneca's oncology haematology business unit head.
ESR1 mutations, which drive resistance to endocrine therapy, emerge in roughly 30% of patients with hormone receptor-positive disease during first-line treatment before scans detect progression.
SERENA-6 used routine blood-based tumour DNA monitoring to catch these mutations early, switching patients onto Etcamah before disease advanced.
The drug is now approved in the EU, Japan, the UAE and Saudi Arabia for this indication, with a US regulatory decision still pending after the FDA extended its review of updated trial data.
Etcamah is the 11th of 20 new medicines AstraZeneca has targeted for launch by 2030.
News Intelligence what this means for the company
AstraZeneca won European Commission approval for Etcamah (camizestrant) combined with a CDK4/6 inhibitor as first-line treatment for ER-positive breast cancer patients who develop ESR1 mutations during initial therapy. The SERENA-6 trial showed a 56% reduction in disease progression or death risk versus standard aromatase inhibitor therapy, extending median progression-free survival to 16.0 months from 9.2 months. Etcamah is now the only next-generation oral selective estrogen receptor degrader approved for first-line use with all three major CDK4/6 inhibitors, addressing an emerging resistance mechanism that affects roughly 30% of patients, and represents the 11th of 20 medicines AstraZeneca targeted for launch by 2030.
The approval expands Etcamah's addressable market into first-line treatment and establishes it as the sole option in its class for this indication across three major CDK4/6 partners, potentially strengthening its competitive position ahead of the pending US regulatory decision. This advance on the 2030 pipeline target supports management's reconfirmed FY 2026 guidance and near-term launch momentum.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
